FDA approves premixed Vaprisol for hyponatremia

VAPRISOL (conivaptan) 20mg/ampule by Astellas Pharma
VAPRISOL (conivaptan) 20mg/ampule by Astellas Pharma

A premixed formulation of Vaprisol (conivaptan HCl injection, from Astellas) has been approved for the treatment of hospitalized patients with euvolemic and hypervolemic hyponatremia. The premixed, single-use Vaprisol formulation offers a 24-month expiration date which is 6-months longer than the currently available Vaprisol ampules.

For more information call (800) 727-7003 or visit www.vaprisol.com.